TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                  Posting of Annual Report and Notice of AGM 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, and development company confirms that its Annual Report 
and Accounts for the year ended 30 June 2020 and the Notice of Annual General 
Meeting ("AGM") has been posted to shareholders. 
 
These documents are available on the Company's website at www.bioventix.com. 
 
The AGM will be held electronically at 2.00 p.m. on 10 December 2020. 
 
As a result of the current UK Government guidance on social distancing and 
prohibiting public gathering over certain numbers, the Company has taken the 
decision that this year unfortunately it will not be possible for shareholders 
to attend the AGM. 
 
Details on how shareholders can vote by proxy are set out in the Notice of 
Annual General Meeting. The Company therefore requests that shareholders 
appoint the Chairman of the meeting as a proxy and provide their voting 
responses in advance of the AGM. 
 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

November 16, 2020 09:16 ET (14:16 GMT)